Explore

White House Plans to Replace FDA Commissioner Marty Makary Amid Criticism

White House Plans to Replace FDA Commissioner Marty Makary Amid Criticism

The White House is preparing to replace FDA Commissioner Marty Makary following months of internal turmoil and external criticism of his leadership. Makary, who was appointed by President Trump, has faced scrutiny over his handling of drug and vaccine approvals, leading to dissatisfaction among pharmaceutical groups and some public health experts. The FDA has experienced significant staff turnover under his leadership, and the administration is considering broader changes to improve the agency's efficiency. The decision to replace Makary is part of a larger effort to address these challenges and restore confidence in the FDA's operations.

Trump plans to fire FDA chief Makary, WSJ reports

Trump plans to fire FDA chief Makary, WSJ reports

May 8 (Reuters) - President Donald Trump has signed off on a plan to fire U.S. Food and Drug Administration Commissioner Marty Makary, the Wall Street Journal reported on Friday, citing people familiar with the matter. The White House and the U.S.

President Trump Approves Plan to Dismiss FDA Commissioner Marty Makary Amid Agency Turmoil

President Trump Approves Plan to Dismiss FDA Commissioner Marty Makary Amid Agency Turmoil

President Donald Trump has reportedly approved a plan to remove FDA Commissioner Marty Makary from his position. This decision follows a period of significant upheaval at the FDA, characterized by unexpected drug rejections and internal conflicts. Makary, who assumed the role in March 2025, has faced criticism for his handling of several high-profile drug applications, including Moderna's mRNA-based flu vaccine. The FDA initially refused to review this application, prompting President Trump to express his dissatisfaction with Makary's leadership. The agency later accepted an amended application. Makary's tenure has also been marked by the controversial implementation of the Commissioner's National Priority Voucher (CNPV) program, which has faced legal scrutiny. The Wall Street Journal reported that Trump's decision is not yet final and could be subject to change.

The Event That Fueled Criticism of COVID Response

The Event That Fueled Criticism of COVID Response

The White House COVID-19 outbreak, which began in September 2020, had significant implications for public perception of the Trump administration's ...

Pentagon begins releasing new files on UFOs and says the public can draw its own conclusions

Pentagon begins releasing new files on UFOs and says the public can draw its own conclusions

The Pentagon has begun releasing new files on UFOs, saying members of the public can draw their own conclusions on “unidentified anomalous phenomena.”

FDA's new playbook: Lots of media announcements but not much rulemaking

FDA's new playbook: Lots of media announcements but not much rulemaking

Health Secretary Robert F. Kennedy Jr. and other health officials have repeatedly announced major changes before any new rules have been drafted

On This Day: COVID-19 Hits White House Leadership

On This Day: COVID-19 Hits White House Leadership

The White House COVID-19 outbreak, which began in September 2020, involved numerous high-profile individuals within the U.S. government. As the vir...

Affordability beats other top issues for MAHA voters, poll finds

Affordability beats other top issues for MAHA voters, poll finds

By Chris Prentice NEW YORK, May 6 (Reuters) - Even for the "Make America Healthy Again" voters who helped usher President Donald Trump back to the White House for a second term, affordability will be top of mind when they vote in November's midterm elections, a new poll found.

FDA Commissioner Defends Replimune Melanoma Drug Rejection Amid Criticism

FDA Commissioner Defends Replimune Melanoma Drug Rejection Amid Criticism

FDA Commissioner Marty Makary has defended the agency's decision to reject Replimune's melanoma therapy RP1, citing adherence to scientific recommendations. The rejection was based on Replimune's use of a single-arm trial, which the FDA deemed insufficient. This decision has sparked controversy and criticism, with some accusing the FDA of being overly restrictive. Makary emphasized that all decisions are based on the recommendations of primary review teams and denied any influence from external pressures. The FDA's transparency policy, which includes publishing rejection letters, aims to increase accountability in the biopharma industry.

Trump signs new counterterrorism strategy that focuses on hemispheric threats

Trump signs new counterterrorism strategy that focuses on hemispheric threats

By Steve Holland WASHINGTON, May 6 (Reuters) - President Donald Trump has signed a new national counterterrorism strategy that focuses in part on the "neutralization" of hemispheric threats and incapacitating cartel operations, top White House adviser Sebastian Gorka said on Wednesday.

Trump wants to paint the Eisenhower office building white. Today, a key federal agency considers it

Trump wants to paint the Eisenhower office building white. Today, a key federal agency considers it

President Donald Trump's plan to put a coat of white paint on the granite exterior of a historic building that's part of the White House complex is getting a hearing by a key federal agency

White House calls Mark Hamill 'sick' after actor posts Trump gravesite image

White House calls Mark Hamill 'sick' after actor posts Trump gravesite image

LOS ANGELES, May 7 (Reuters) - The White House called "Star Wars" star Mark Hamill "one sick individual" on Thursday after an AI-generated image of U.S. President Donald Trump in a shallow grave was posted on one of the actor's social media accounts.